Academic Journal
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
| العنوان: | Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group |
|---|---|
| المؤلفون: | Redondo, Alba M., Valcárcel, David, González‐Rodríguez, Ana P., Suárez‐Lledó, María, Bello, José L., Canales, Miguel, Gayoso, Jorge, Colorado, Mercedes, Jarque, Isidro, del Campo, Raquel, Arranz, Reyes, Terol, María J., Rifón, José J., Rodríguez, María J., Ramírez, María J, Castro, Nerea, Sánchez, Andrés, López‐Jiménez, Javier, Montes‐Moreno, Santiago, Briones, Javier, López, Aurelio, Palomera, Luis, López‐Guillermo, Armando, Caballero, Dolores, Martín, Alejandro |
| المساهمون: | Mundipharma |
| المصدر: | British Journal of Haematology ; volume 184, issue 5, page 797-807 ; ISSN 0007-1048 1365-2141 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2018 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Summary We conducted a phase 2 trial to evaluate the safety and efficacy of bendamustine instead of BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) regimen (BendaEAM) as conditioning for autologous stem‐cell transplantation (ASCT) in patients with aggressive lymphomas. The primary endpoint was 3‐year progression‐free survival (PFS). Sixty patients (median age 55 [28–71] years) were included. All patients (except one who died early) engrafted after a median of 11 (9–72) and 14 (4–53) days to achieve neutrophil and platelet counts of >0.5 × 10 9 /l and >20 × 10 9 /l, respectively. Non‐relapse mortality at 100 days and 1 year were 3.3% and 6.7%, respectively. With a median follow‐up of 67 (40–77) months, the estimated 3‐year PFS and overall survival (OS) were 58% and 75%, respectively. Patients in partial response at study entry had significantly worse PFS and OS than patients who underwent ASCT in complete metabolic remission, and this was the only prognostic factor associated with both PFS (Relative risk [RR], 0.27 [95% confidence interval {CI} [0.12–0.56]) and OS (RR, 0.40 [95% CI 0.17–0.97]) in the multivariate analysis. BendaEAM conditioning is therefore a feasible and effective regimen in patients with aggressive lymphomas. However, patients not in complete metabolic remission at the time of transplant had poorer survival and so should be considered for alternative treatment strategies. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1111/bjh.15713 |
| الاتاحة: | http://dx.doi.org/10.1111/bjh.15713 https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fbjh.15713 https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15713 https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bjh.15713 |
| Rights: | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| رقم الانضمام: | edsbas.9CA21EF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/bjh.15713 |
|---|